Author

Elizabeth A. Schackmann

Observed names: E Schackmann, E. A. Schackmann, EA Schackmann, Elizabeth Schackmann

Institutions: University of Washington, Boise VA Medical Center, Office of Rural Health, Veterans Administration

Observed institutions: Albert Einstein College of Medicine, University of Washington, University of Utah, Veterans Health Administration, University of Washington Medical Center, Boise VA Medical Center, Stanford Medicine, Myriad Genetics, Office of Rural Health, Veterans Administration, University of Hong Kong, Stanford University

OpenAlex ID: A5077023877

Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1 / 2 Mutation–Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105

2015 · Melinda L. Telli, Kristin C. Jensen, et al. · Journal of Clinical Oncology · 233

PDF

Online Tool to Guide Decisions forBRCA1/2Mutation Carriers

2012 · Allison W. Kurian, Diego F. Munoz, et al. · Journal of Clinical Oncology · 93

Tumor BRCA1 Reversion Mutation Arising during Neoadjuvant Platinum-Based Chemotherapy in Triple-Negative Breast Cancer Is Associated with Therapy Resistance

2017 · Anosheh Afghahi, Kirsten M. Timms, et al. · Clinical Cancer Research · 73

A clinical trial of lovastatin for modification of biomarkers associated with breast cancer risk

2013 · Shaveta Vinayak, Erich J. Schwartz, et al. · Breast Cancer Research and Treatment · 36

Breast cancer risk factors differ between Asian and white women with BRCA1/2 mutations

2012 · Monique A. de Bruin, Ava Kwong, et al. · Familial Cancer · 33

PrECOG 0105: Final efficacy results from a phase II study of gemcitabine (G) and carboplatin (C) plus iniparib (BSI-201) as neoadjuvant therapy for triple-negative (TN) and BRCA1/2 mutation-associated breast cancer.

2013 · Melinda L. Telli, Kristin C. Jensen, et al. · Journal of Clinical Oncology · 31

Feasibility evaluation of an online tool to guide decisions for BRCA1/2 mutation carriers

2012 · Elizabeth A. Schackmann, Diego F. Munoz, et al. · Familial Cancer · 21

C/EBPβ-1 promotes transformation and chemoresistance in Ewing sarcoma cells

2017 · Jamie D. Gardiner, Lisa M. Abegglen, et al. · Oncotarget · 17

PDF

The Evolution of Internal Medicine Chief Residents: A 20-Year Multicenter Study

2024 · Tyler J. Albert, Helene Starks, et al. · The American Journal of Medicine · 8

Near‐peer coaching tool for new senior residents

2020 · Courtney Tuegel, Elizabeth Schackmann, et al. · Medical Education · 5

P3-14-08: A Phase II Study of Gemcitabine and Carboplatin (GC) Plus Iniparib (BSI-201) as Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer.

2011 · ML Telli, AW Kurian, et al. · Cancer Research · 2

Prolonged Hospitalization and Adverse Events in Veterans Awaiting Guardianship: A Retrospective Cohort Analysis

2025 · Andrea Smeraglio, Daniel Heppe, et al. · Journal of General Internal Medicine · 1

Invasive Mucormycosis in an Immunocompetent Non-Diabetic with Severe Acidosis (P5.086)

2018 · Akanksha Sharma, Jenny Siv, et al. · Neurology · 1

Medically ready for discharge: A multicenter Veterans Health Administration assessment of hospitalized patients

2026 · Michelle M. Guidry, Matthew Tuck, et al. · Journal of Hospital Medicine

Association of facility‐ and hospital medicine group‐level characteristics on the impact of burnout among hospitalists in the Veteran's Health Administration

2026 · Joel C. Boggan, Jacqueline M. Ferguson, et al. · Journal of Hospital Medicine

Career choices of ambulatory chief residents: A 20-year, multicenter study

2025 · Paul B. Cornia, Helene Starks, et al. · The American Journal of Medicine

Data from Tumor BRCA1 Reversion Mutation Arising during Neoadjuvant Platinum-Based Chemotherapy in Triple-Negative Breast Cancer Is Associated with Therapy Resistance

2023 · Anosheh Afghahi, Kirsten M. Timms, et al.

Data from Tumor BRCA1 Reversion Mutation Arising during Neoadjuvant Platinum-Based Chemotherapy in Triple-Negative Breast Cancer Is Associated with Therapy Resistance

2023 · Anosheh Afghahi, Kirsten M. Timms, et al.

Appendix 1 from Tumor BRCA1 Reversion Mutation Arising during Neoadjuvant Platinum-Based Chemotherapy in Triple-Negative Breast Cancer Is Associated with Therapy Resistance

2023 · Anosheh Afghahi, Kirsten M. Timms, et al.

PDF

Appendix 1 from Tumor BRCA1 Reversion Mutation Arising during Neoadjuvant Platinum-Based Chemotherapy in Triple-Negative Breast Cancer Is Associated with Therapy Resistance

2023 · Anosheh Afghahi, Kirsten M. Timms, et al.

Abstract 483: Functional validation of CEBPB as an oncogenic target of EWS-FLI1 in Ewing sarcoma

2015 · Lisa M. Abegglen, Jamie D. Gardiner, et al. · Cancer Research

P4-10-10: Breast Cancer Risk Factors among Asian Versus Caucasian Women with BRCA1/2 Mutations.

2011 · Bruin MA de, A Kwong, et al. · Cancer Research

Utilizing BRCA1/2 mutation status to select patients for breast cancer clinical trials: Experience from a prospective phase II trial.

2011 · E. A. Schackmann, S. Vinayak, et al. · Journal of Clinical Oncology

Works count: 23

Citation count: 554

H-index: 8

I10-index: 8